Specificities of type 2 diabetes in the elderly

被引:0
作者
Virally, Marie [1 ]
Laloi-Michelin, Marie [1 ]
Kevorkian, Jean-Philippe [1 ]
Bitu, Julie [1 ]
Guillausseau, Pierre-Jean [1 ]
机构
[1] Hop Lariboisiere, Serv Med B, F-75010 Paris, France
来源
SANG THROMBOSE VAISSEAUX | 2011年 / 23卷 / 08期
关键词
Type; 2; diabetes; elderly patients; treatment; INTENSIVE GLYCEMIC CONTROL; GLUCOSE CONTROL; HYPOGLYCEMIA; ADVANCE; ACCORD;
D O I
10.1684/stv.2011.0642
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Specificities of type 2 diabetes in the elderly The prevalence of type 2 diabetes (DT2) increases significantly with the age. Recent data show that 50% of patients with type 2 diabetes are over 65 years old, and 25% are over 75 years old. Aging is not the same in different people or in different patients. Aging may be classified in three types: successful aging, pathological aging and physical dependency. Frailty is an intermediate state. The elderly diabetic is at high risk because of the cardiovascular and functional complications (neuropathy, visual deficit), vascular risk factors (hypertension, dyslipidemia) and mental disorders (cognitive disorders, dementia, depression, and brain damage). It is important to detect the clinical signs of frailty in elderly diabetics because gerontological intervention has been shown to be effective in preventing loss of autonomy and in improving the quality of life. Treatment is difficult because it has to take into account the risk/benefit ratio. The side effects of drugs, especially hypoglycaemia, may be dangerous in the elderly. Patient education remains essential and must be specific. Dietary advice, physical activity and medical treatment must be personalized and are important for blood sugar control, nutritional balance and the chances of a successful aging.
引用
收藏
页码:409 / 415
页数:7
相关论文
共 34 条
  • [1] New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly Role of Incretin Therapies
    Abbatecola, Aiigela M.
    Maggi, Stefania
    Paolisso, Giuseppe
    [J]. DRUGS & AGING, 2008, 25 (11) : 913 - 925
  • [2] Bauduceau B, 2008, MED MAL METAB, V2, pS69
  • [3] The Barrier of Hypoglycemia in Diabetes
    Cryer, Philip E.
    [J]. DIABETES, 2008, 57 (12) : 3169 - 3176
  • [4] Severe iatrogenic hypoglycemia in type 2 diabetes mellitus
    Cryer, Philip E.
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (01): : 4 - 5
  • [5] Detournay B, 2008, DIABETOLOGIA, V51, pS421
  • [6] Intensive glycemic control in the ACCORD and ADVANCE trials
    Dluhy, Robert G.
    McMahon, Graham T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) : 2630 - 2633
  • [7] Doucet J, 2005, DIABETES METAB, V31, pS98
  • [8] Doucet J, 2011, DIABETES METAB A, V102, pA36
  • [9] Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
    Duckworth, William
    Abraira, Carlos
    Moritz, Thomas
    Reda, Domenic
    Emanuele, Nicholas
    Reaven, Peter D.
    Zieve, Franklin J.
    Marks, Jennifer
    Davis, Stephen N.
    Hayward, Rodney
    Warren, Stuart R.
    Goldman, Steven
    McCarren, Madeline
    Vitek, Mary Ellen
    Henderson, William G.
    Huang, Grant D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) : 129 - U62
  • [10] Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743